Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.2% – Still a Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price rose 7.2% during trading on Wednesday . The stock traded as high as $2.53 and last traded at $2.53. Approximately 905,433 shares traded hands during trading, a decline of 58% from the average daily volume of 2,142,431 shares. The stock had previously closed at $2.36.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SANA. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Sana Biotechnology in a research note on Monday, November 11th. Citigroup raised their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th.

Sana Biotechnology Trading Up 7.6 %

The stock has a market cap of $567.10 million, a P/E ratio of -1.81 and a beta of 1.44. The business’s 50 day moving average price is $3.82 and its two-hundred day moving average price is $5.44.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. As a group, analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Insider Transactions at Sana Biotechnology

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 31.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SANA. ProShare Advisors LLC increased its position in shares of Sana Biotechnology by 14.8% during the first quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock worth $327,000 after buying an additional 4,210 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Sana Biotechnology by 20.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after purchasing an additional 5,090 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Sana Biotechnology by 17.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock worth $146,000 after purchasing an additional 5,338 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Sana Biotechnology by 2.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock valued at $1,056,000 after acquiring an additional 6,823 shares during the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of Sana Biotechnology by 36.7% during the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after purchasing an additional 9,940 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.